1. 1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. The Lancet. 2005 Aug 6;366(9484):491-505. 2. Sorosky JI. Endometrial cancer. Obstetrics & Gynecology. 2008 Feb 1;111(2):436-47. 3. Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Herzog TJ, Shahin FA, SGO Clinical Practice Endometrial Cancer Working Group. Endometrial cancer: a review and current management strategies: part II. Gynecologic oncology. 2014 Aug 1;134(2):393-402. 4. Saso S, Chatterjee J, Georgiou E, Ditri AM, Smith JR, Ghaem-Maghami S. Endometrial cancer. Bmj. 2011 Jul 6;343. 5. Purdie DM, Green AC. Epidemiology of endometrial cancer. Best practice & research Clinical obstetrics & gynaecology. 2001 Jun 1;15(3):341-54. 6. Braun MM, Overbeek-Wager E, Grumbo RJ. Diagnosis and management of endometrial cancer. American family physician. 2016 Mar 15;93(6):468-74. 7. Wright JD, Medel NI, Sehouli J, Fujiwara K, Herzog TJ. Contemporary management of endometrial cancer. The Lancet. 2012 Apr 7;379(9823):1352-60. 8. Suarez AA, Felix AS, Cohn DE. Bokhman Redux: Endometrial cancer “types” in the 21st century. Gynecologic oncology. 2017 Feb 1;144(2):243-9. 9. Wilczyński M, Danielska J, Wilczyński J. An update of the classical Bokhman's dualistic model of endometrial cancer. Przegla̜d Menopauzalny= Menopause Review. 2016 Jun;15(2):63. 10. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer research. 2005 Dec 1;65(23):10669-73. 11. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer control. 2009 Jan;16(1):8-13. 12. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Modern Pathology. 2000 Mar;13(3):295-308. 13. Moher D, Altman DG, Liberati A, Tetzlaff J. PRISMA statement. Epidemiology. 2011 Jan 1;22(1):128. 14. Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, Britton H, Grevenkamp F, Karnezis A, Yang W, Lum A. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Annals of Oncology. 2018 May 1;29(5):1180-8. 15. Yuan J, Mao Z, Lu Q, Xu P, Wang C, Xu X, Zhou Z, Zhang T, Yu W, Dong S, Wang Y. Hypermethylated PCDHGB7 as a Biomarker for Early Detection of Endometrial Cancer in Endometrial Brush Samples and Cervical Scrapings. Frontiers in Molecular Biosciences. 2021;8. 16. Perez‐Sanchez C, Colas E, Cabrera S, Falcon O, Sanchez‐del‐Río A, García E, Fernández‐de‐Castillo L, Muruzabal JC, Alvarez E, Fiol G, González C. Molecular diagnosis of endometrial cancer from uterine aspirates. International journal of cancer. 2013 Nov 15;133(10):2383-91. 17. Kumar NU, Sridhar MG, Srilatha K, Habebullah S. CA 125 is a better marker to differentiate endometrial cancer and abnormal uterine bleeding. African health sciences. 2018 Nov 29;18(4):972-8. 18. Nicklin J, Janda M, Gebski V, Jobling T, Land R, Manolitsas T, McCartney A, Nascimento M, Perrin L, Baker JF, Obermair A. The utility of serum CA‐125 in predicting extra‐uterine disease in apparent early‐stage endometrial cancer. International journal of cancer. 2012 Aug 15;131(4):885-90. 19. Liu J, Han L, Jiao Z. The diagnostic value of human epididymis protein 4 for endometrial cancer is moderate. Scientific Reports. 2021 Jan 12;11(1):1-7. 20. Dong C, Liu P, Li C. Value of HE4 combined with cancer antigen 125 in the diagnosis of endometrial cancer. Pakistan Journal of Medical Sciences. 2017 Jul;33(4):1013. 21. Cocco E, Bellone S, El‐Sahwi K, Cargnelutti M, Buza N, Tavassoli FA, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A: a novel biomarker for endometrial cancer. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2010 Feb 15;116(4):843-51. 22. Baser E, Togrul C, Ozgu E, Ayhan S, Caglar M, Erkaya S, Gungor T. Sperm-associated antigen 9 is a promising marker for early diagnosis of endometrial cancer. Asian Pacific Journal of Cancer Prevention. 2013;14(12):7635-8. 23. Qin R, Liao M, Qin W, Wang J, Zheng F, Ma N, Zhao Y, Qin A. The Diagnostic value of Serum YKL-40 in Endometrial Cancer: a meta-analysis. Biomarkers. 2022 Jan 3(just-accepted):1-4. 24. Tian W, Zhu Y, Wang Y, Teng F, Zhang H, Liu G, Ma X, Sun D, Rohan T, Xue F. Visfatin, a potential biomarker and prognostic factor for endometrial cancer. Gynecologic oncology. 2013 Jun 1;129(3):505-12. 25. Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, Sompolska-Rzechuła A, Machaliński B, Menkiszak J. Circulating serum level of visfatin in patients with endometrial cancer. BioMed Research International. 2018 Oct;2018. 26. Urick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer. Nature Reviews Cancer. 2019 Sep;19(9):510-21. 27. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008;110(2):196-20